SeqOnce Biosciences

SeqOnce Biosciences

Open  for investment

About this raise

SeqOnce Biosciences, with a valuation of $25 million, is raising funds on Republic. It is an innovative DeepTech company with expertise in Next-Generation Sequencing (NGS), PCR-based applications (qPCR), and novel tech development. SeqOnce Biosciences aims to make sample preparation for gene sequencing more efficient and introduce new assay opportunities for respiratory pathogens, women’s health, and pathogen screening. The company has launched nine products, developed two new novel technologies, and generated $45 million in revenue to date. Christopher Angermayer and Joseph Dunham founded SeqOnce Biosciences in February 2014. The current crowdfunding campaign has a minimum target of $50,000 and a maximum target of $1.24 million. The campaign proceeds will be used for capital expenditure, debt service, manufacturing expansion, hiring, and working capital.

Expand

Investment Overview

Committed this round: $112,361

Deal Terms

Total Commitments

Platform
Republic
Start Date
02/19/2025
Close Date
04/30/2025
Min. Goal
$50,000
Max Goal
$1,235,000
Min. Investment

$100

Security Type

SAFE

Series

Seed

SEC Filing Type

RegCF    Open SEC Filing

Valuation Cap

$25,000,000

Discount

20%

Company & Team

Company

Year Founded
2014
Industry
Healthcare & Pharmaceuticals
Tech Sector
Biotech
Distribution Model
B2B
Margin
High
Capital Intensity
Low
Location
Carlsbad, California
Business Type
High Growth
Company Website
Visit Website

Team

Employees
11
Prior Founder Exits?
No
Founder Name
Chris Angermayer
Title
President & CEO
Founder Name
Joseph Dunham
Title
Chief Science Officer

Financials

as of January 31, 2025
 Revenue -43% YoY
$1,300,000
 Monthly Burn
$194,758
 Runway
0.1 months
Gross Margin
92%

Summary Profit and Loss Statement

FY 2023 FY 2022

Revenue

$2,585,633

$16,656,372

COGS

$207,519

$11,095,933

Tax

$0

$0

 

 

Net Income

$-2,337,090

$-1,530,863

Summary Balance Sheet

FY 2023 FY 2022

Cash

$254,512

$4,435,703

Accounts Receivable

$329,358

$259,793

Total Assets

$2,688,956

$7,068,829

Short-Term Debt

$1,496,972

$3,008,600

Long-Term Debt

$0

$0

Total Liabilities

$1,496,972

$3,008,600

Create a free account today to gain access to Kingscrowd analytics and financials.

Upgrade to gain access

Pay Monthly
Annually (2 months free)

Edge

$12.50 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific Kingscrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings Kingscrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars

Company Funding & Growth

Funding history

Total Prior Capital Raised
$881,831
VC Backed?
Yes
Close Date Platform Valuation Total Raised Security Type Status Reg Type
04/30/2025 Republic $25,000,000 $112,361 SAFE Active RegCF
Create a free account today to gain access to Kingscrowd analytics.
Founders: enhance your startup's credibility on Kingscrowd. Create an account to claim this raise page.
Add to portfolio
SeqOnce Biosciences on Republic 2025
Platform: Republic
Security Type: SAFE
Valuation: $25,000,000

Follow company

Follow SeqOnce Biosciences on Republic 2025

Buy SeqOnce Biosciences's Deal Report

SeqOnce Biosciences Deal Report

Get Kingscrowd's comprehensive report on SeqOnce Biosciences including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether SeqOnce Biosciences is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the SeqOnce Biosciences deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge